Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | JUN | P05412 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067793 | 0.87 | ROCK2 (0.34) | RIPK1SSTR4JUNCDK2MAPK8 | |
| SCHEMBL14712327 | 0.77 | PLK4 (0.33) | SSTR4 | |
| SCHEMBL13059351 | 0.75 | SSTR4 (0.30) | SSTR4 | |
| SCHEMBL14327554 | 0.75 | — | — | |
| SCHEMBL13060172 | 0.73 | IRAK4 (0.32) | — | |
| SCHEMBL13059375 | 0.73 | HCRTR1 (0.31) | SSTR4 | |
| SCHEMBL10067408 | 0.72 | BCL6 (0.34) | JUNCDK2MAPK8MAPK9MAPK10 | |
| SCHEMBL13059470 | 0.71 | PLK4 (0.43) | SSTR4 | |
| SCHEMBL13215364 | 0.71 | PLK4 (0.34) | SSTR4 | |
| SCHEMBL13060167 | 0.69 | SSTR4 (0.30) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | JAK3, JAK1, JAK2 | RIPK1 214/4885SSTR4 3684/4885JUN 1095/4885 |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | JAK3, JAK1, JAK2 | RIPK1 214/4885SSTR4 3684/4885JUN 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.